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Whole-genome sequences of Plasmodium spp. have helped redefine malaria research, including initiatives
that seek to develop drugs, vaccines, and other antimalarial therapies. The problems caused by malaria
were brought to the public’s attention once more on World Malaria Day (April 25). Unfortunately, the current
impact of genome-informed research is not as great as might have been hoped, and the reasons for this and
continuing challenges are discussed.April 25, 2008, as well as being my son’s
second birthday, was the first World Malaria
Day,asomber reminder toa largelyuncaring
(developed) world that another one million
young children in rural sub-Saharan Africa
have died from this disease in the previous
12 months, and nearly a billion more have
been affected in and around the tropics.
The event featured on news bulletins and
has stimulated articles such as this one,
but the sober fact is that this particular plight
of the tropics and especially Africa will fade
from public consciousness until the next re-
minder. Every once in a while that reminder
is not a public awareness action such as
World Malaria Day, but news of an advance
that offers promise of an eventual treatment.
On these occasions one of the cohort of sci-
entists and organizations who dedicate their
working lives to the search for treatments
pops his or her head above the research
trenches and allows the world an optimistic
insight into his or her endeavors, e.g., the
recent trials of the RTS,S/AS02 candidate
vaccine formulation developed by Glaxo-
Smith-Kline (Alonso et al., 2005). These in-
stances remain quite rare, and this article at-
tempts to explain why this is so, but it is also
concerned with whether or not and when we
can reasonably expect an increased out-
put of translational medicine. Furthermore,
are genome-informed technologies making
any contribution to these efforts, and what
would be necessary to improve the likeli-
hood that they might?
Plasmodium Genomes
and Their Exploitation
In 2002, the virtually complete 23 Mb
genome of the lethal human parasite280 Cell Host & Microbe 3, May 2008 ª2008Plasmodium falciparum was published
(Gardner et al., 2002). Although, strictly
speaking, this genome is still incomplete
and limited by being a sequence of a cul-
ture-adapted clone (3D7) of a strain (NF54)
of unknown provenance (but most proba-
bly African), this was a true landmark in
malaria research. For the first time re-
searchers could look at the complete gene
content of the 14 linear chromosomes of
the parasite and deduce, for example,
metabolic pathways and identify novel
drug targets and new potential vaccine
candidates (see below). The organization
of the chromosomes was similar, with
biologically conserved genes occupying
more central regions of each chromo-
some and those multigene families given
over to antigenic variation being largely
restricted to the subtelomeric peripheries.
The study also helped validate the use
of Plasmodium models as systems of
study relevant to clinical questions, since
a significant genome sequence of a rodent
malaria parasite (RMP),Plasmodium yoelii
(Carlton et al., 2002), was published
alongside that of P. falciparum and subse-
quent genome information from other
RMPs has been published (Hall et al.,
2005). A high degree of synteny and func-
tional orthology was demonstrated be-
tween the genomes, with the central core
of the chromosomes housing the 4500
of the 5300 genes in a typical Plasmodium
genome that are conserved, including all
major drug targets and the majority of cur-
rent human parasite vaccine candidates.
Therefore, we can expect that all Plasmo-
dium species have a similar degree of
conservation, that their biochemistry willElsevier Inc.be very similar, and that research on drug
resistance and vaccine antigen function
in model systems will generally be infor-
mative.
This comprehensive characterization
of Plasmodium genomes, substantially
fleshed out with detailed studies on world-
wide P. falciparum genetic variation, has
served as a springboard for the introduc-
tion of ‘‘-omics’’-based approaches to
parasite characterization, and various
stage-specific proteomes and transcrip-
tomes have been produced and exploited.
Even greater detail has been generated
by Plasmodium organellar proteomes (re-
viewed in Sims and Hyde, 2006), and the
annotated gene predictions have been
used to generate large-scale data sets
such as protein-protein interactomes
(LaCount et al., 2005) and high-throughput
structural genomics programs (Gileadi
et al., 2007). Site-directed genetic trans-
formation of a number of Plasmodium
species, includingP. falciparum, had been
realized well before 2002 (Meissner et al.,
2007), and such studies have been greatly
fueled by the comparative genomics of
Plasmodium. Increasing sophistication of
genetic manipulation of Plasmodium and
subsequent analysis of phenotype has
led to a wealth of discoveries ranging
from the basic general biological behavior
of the parasite in vivo to fundamental
molecular discoveries that are happily too
numerous to catalog here.
Drug Discovery
Unfortunately, in the years since 2002 the
actual contribution of genome-informed
experimentation to imminently testable
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vaccines are the obvious possibilities)
has been at best patchy. The initial prom-
ise was very encouraging; the annotation
of the P. falciparum genome at the time
of publication was already advanced
enough to point to organizational idiosyn-
crasies and evolutionary histories and
permitted the creation of a metabolic
profile for this and related parasites. The
most recent thought is that Plasmodium
parasites are an evolutionary hybrid of
a standard eukaryote and a photosyn-
thetic red algae (Moore et al., 2008).
Thus, metabolic pathways distinct from
those of the host were defined and indi-
cated that certain antimicrobial agents
already in existence and FDA approved
would have antimalarial properties that
might be exploited as significant lead
structures for drug discovery (Gardner
et al., 2002). For example, triclosan (an
antibacterial in use in both toothpaste
and soap) is an inhibitor of fatty acid
elongation that has specific antimalarial
properties (Surolia and Surolia, 2001).
Likewise, the plant-like pathway of meval-
onate-independent isoprenoid synthesis
is contained within a specialized plastid-
relict organelle, the apicoplast, and inhib-
itors of the pathway such as fosmidomy-
cin are active against malaria parasites
and serve as interesting lead inhibitors
for further development (Jomaa et al.,
1999). The genome annotation also
helped underpin and expand ongoing
drug discovery programs, for example,
those based upon the fact that blood-
stage Plasmodium parasites synthesize
huge amounts of phospholipid (specifi-
cally phosphatidylcholine), and the asso-
ciated transport and synthetic processes
established by the parasite in the infected
erythrocyte are amenable to drug inter-
vention (Wengelnik et al., 2002). However,
despite these jumpstarts for drug discov-
ery, progress toward the development of
clinically active compounds is deliberate
and fraught. The requirements for target
identification and validation in parasitic
diseases were laid down over a decade
ago (Wang, 1997) and remain valid. These
requirements are activity, toxicity, tolera-
bility, and cost. The biology of host and
parasite frequently contributes in no small
part to what might be seen as frustratingly
slow progress. Promising leads that in-
hibit their validated target recombinant
protein must then be shown to have activ-ity against (in order) the human parasite
cultured in vitro and a RMP (typically Plas-
modium berghei) in vivo, followed by pri-
mate studies and animal toxicology stud-
ies, before clinical trials may be initiated.
Furthermore, the costs of drug production
are a critical consideration, as the target
patient cannot afford a drug that costs
even a dollar per day. Consequently, it has
been proposed that any drug candidate
must be simple to manufacture (probably
no more than a two-step synthesis with
>80% yield) and use a readily available
cheap starting material (http://www.
antimal.eu/). Perhaps as a consequence
of such constraints, while the Drugs for
Neglected Diseases Initiative (DNDi;
http://www.dndi.org/) has many projects
in its drug discovery portfolio that focus
on the combinatorial redeployment of
existing drugs, none concerns the devel-
opment of novel chemical inhibitors of
malaria parasites. Likewise, the portfolio
of the Medicines for Malaria Venture
(MMV; http://www.mmv.org/) is smaller
now than it was 3 years ago and concen-
trates on reformulations; the search for
novel chemical entities as inhibitors is
well down the pipeline. In addition, the ar-
gument has been made that many of the
current drugs used to treat parasitic dis-
eases would not pass current regulations
associated with drug discovery (Renslo
and McKerrow, 2006), which only empha-
sizes the crying need for more discovery
(i.e., more funding). Other, more modestly
funded multicenter initiatives exist (e.g.,
Antimal, a European Commission-funded
program on its first 5 year cycle), which,
as a consequence of the caveats and
principles listed above, have adopted a
highly attritional strategy where no pro-
jects and compounds other than those
meeting strict criteria for production and
efficacy will continue to be supported.
Such a strategy is high risk but at least
generally focuses on the development of
novel antimalarials. Thus, it is frustrating
that more rapid progress has not been
possible, since we are not short of poten-
tial targets; 390 articles are listed by
PubMed (http://www.ncbi.nlm.nih.gov/
sites/entrez) in a search (‘‘drug’’ AND ‘‘tar-
get’’ AND ‘‘Plasmodium’’) that have been
published since the P. falciparum genome
was published, demonstrating commu-
nity awareness of the potential and impor-
tance of such studies. A further hindrance
to progress is the regulation of theCell Host & Mprocess of translational medicine, some-
thing that applies equally to all of drug
development, not just parasitic diseases.
The pathway to clinical approval of
a drug is highly regulated and very ex-
pensive; a successful drug could easily
cost $500–$2000 million to develop from
scratch. If we have a normal attrition
rate, then just 0.05% of candidates will
be clinically successful, and so at the
moment we do not even have close to
the required number of candidate com-
pounds or the finances to drive the pro-
cess. The public-private partnerships
that underpin DNDi and MMV seek to
drive down the costs through the engage-
ment of big pharma and their generous
provision of facilities and combinatorial
libraries, but that can only offset so much
of the inevitable costs.
One alternative, given that one of the
most successfully exploited drug targets
of the malaria parasite is the highly con-
served dihydrofolate reductase, could be
that there may be clinically approved
drugs that have failed to successfully treat
the medical condition for which they were
developed but may be effective against
malaria. This approach is probably under-
exploited.
Vaccine Development
The pathway of malaria vaccine develop-
ment is described in detail by a document
available from the Malaria Vaccine Initiative
(MVI; http://www.malariavaccineroadmap.
net/pdfs/vaccine_steps.pdf). Successful
vaccine validation is a multistep, poten-
tially iterative process that can cost as
much as $500 million and involve 50 to
100,000 volunteers. An important addi-
tional consideration is that the vaccine
will be primarily administered to children,
so additional safety and efficacy tests
must be carried out once a candidate for-
mulation has been successfully trialed in
adults. A crucial difficulty in malaria vac-
cine development is the complexity of
the parasite, which has four different life-
cycle stages against which a vaccine
might be targeted. Each of these stages
has a unique surface protein complement,
and so a monovalent vaccine is also likely
to be stage specific. Current vaccine
candidates are numerous (http://www.
who.int/vaccine_research/RainbowTable_
ClinicalTrials_November2007.pdf) but
limited to antigens that were discovered
before the full genome sequence oficrobe 3, May 2008 ª2008 Elsevier Inc. 281
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ing centers. It is quite clear that at current
levels of funding we cannot afford to fully
trial what we already have in our hands.
Most current vaccine candidates are
monovalent, single-stage reagent studies,
and it is widely accepted that a multistage
polyvalent vaccine would be ideal. The ex-
isting combinations being tested or pro-
posed for testing are seemingly concocted
from the range available to the organization
responsible for the test. So are there bet-
ter ways to decide how and when we com-
bine candidates and test them? Unfortu-
nately, preclinical testing is worrisome, as
there are no accepted correlates of clinical
immunity and so approval for further trials
of candidates or, perhaps more crucially
given the limited availablefinance, the early
elimination from further consideration is
difficult. The field has had a track record
of overoptimism when it comes to predict-
ing the arrival of vaccines, a trait that has
at times both damaged funding for basic
research and affected endemic-region
health policies through reduction of fund-
ing prioritization to malaria, and repeats
of this must be avoided. Thus, the way for-
ward is unclear, and perhaps new and
transparent standards need to be agreed
upon so that progress can be made.
Suchprogresswould includereachingara-
tional decision about prioritization of new
targets revealed by the genome sequence
allied to indicators of patterns of expres-
sion (e.g., proteomes and microarrays).
For example, there are currently 26 genes
in the P. falciparum genome that are anno-
tated to encode a protein with a signal pep-
tide transcribed maximally and detected
asa protein in the merozoite form, which in-
vades erythrocytes and is a prime vaccine
candidate source (search performed on
http://www.plasmodb.org/). Other consid-
erations for inclusion and exclusion could
be the degree of polymorphism in P. falci-
parum and the extent of conservation
across the Plasmodium genus. There are
equally many candidates for each stage
of the parasite that might be targeted, so
the task of selection is daunting.
Attenuated parasite vaccines sidestep
the issues concerning choice of antigen
and have been shown to be successful
with RAS, radiation-attenuated sporozo-
ites (the infectious particle delivered to
the blood by the mosquito). The appro-
priately irradiated sporozoite targets the
liver but only develops partially before282 Cell Host & Microbe 3, May 2008 ª2008arresting and lingering for months in the
liver. Such arrested forms stimulate an
impressive level of immunity that affords
sterile protection from further sporozoite
challenge for up to 1 year (Nussenzweig
et al., 1967; Rieckmann, 1990). Such im-
munity is stage specific, as it does not
protect hosts that are mechanically chal-
lenged with blood-stage parasites. There
are obvious problems with such a vaccine,
including delivery; how could sufficient
numbers of ‘‘clean’’ sporozoites be pre-
pared, irradiated, and delivered to dis-
ease-endemic countries in order to initiate
meaningful vaccination (Luke and Hoff-
man, 2003)? Impressively, many of these
questions have been answered by Sana-
ria, a company dedicated to solving just
these issues (http://www.sanaria.com/).
Worryingly, the level of irradiation is criti-
cal—too much, and the parasite is killed
and fails to elicit protective immune re-
sponses, too little, and the sporozoite re-
mains infectious. Here, genome-informed
technologies have made their most pro-
ductive contribution to malaria therapies.
Four conserved genes (uis3, uis4, p36,
and p36p) have been identified that
when individually deleted from the RMP
P. berghei genome give rise to genetically
attenuated sporozoites (GAS) that elicit
precisely the same type of long-lasting
protective immune responses as RAS
(Mueller et al., 2005; van Dijk et al., 2005).
Programs sponsored by both the Bill &
Melinda Gates Foundation and Dutch
agencies (TI Pharma), in partnership with
Sanaria and the scientists involved in the
rodent studies, now seek to attempt to
validate the GAS approach with the ortho-
logs of these genes in P. falciparum.
Blood-stage attenuated parasites might
also be developed but would have to be
developed in animal models first, and it
is questionable whether results in model
systems would be truly predictive of pro-
tection against P. falciparum infection in
humans.
Conclusions
Parasitic diseases have been termed ne-
glected diseases; they are also diseases
of poverty. HIV/AIDS (human immunode-
ficiency virus/acquired immunodeficiency
syndrome) is a relative newcomer to the
field of human infectivity, yet it is already
the subject of huge investment (http://news.
bbc.co.uk/1/hi/world/americas/7327694.
stm), in no small part because it was firstElsevier Inc.detected in the developed nations of the
world and thus there is a direct and imme-
diate understanding of the impact of the
disease and personal experience on the
part of those who are empowered to liber-
ate up to $50 billion. In the developed na-
tions, such intimate personal experience
is largely lacking for malaria and similar
diseases, and perhaps this explains why
they do not attract the same levels of en-
gagement and funding. A further explana-
tion is that you can be reasonably certain
of what your money will buy in terms of
intervention measures delivered for HIV/
AIDS. This certainty with malaria treat-
ment is distant, but without substantial
further investment along the full length of
the treatment development pipelines,
coupled with hard choices and the impo-
sition of more stringent self-review of
what our pipelines contain, we will not
be able to deliver any progress in the fore-
seeable future. Basic biological research
aimed at understanding the biology of
the parasite and the nature of its interac-
tions with both the host and vector should
be considered an essential early phase
of therapy development and attract fund-
ing commensurate with its importance.
The Abuja Declaration (http://www.rbm.
who.int/docs/abuja_declaration_final.htm)
signed in 2000 in Nigeria called for the gov-
ernments and nongovernmental organiza-
tions (NGOs) of the world to combat ma-
laria, including committing $1 billion per
year of new funding resources to the cause
to help ‘‘Roll Back Malaria.’’ This funding
commitment has largely been unmet and
is indicative of the problem of insufficient
funding. World Malaria Day is one step to-
ward improving awareness, but the cam-
paigns have to be sustained and varied,
and research must be well supported fi-
nancially and rigorously overseen as indi-
cated. Lastly, we should not forget that
we are dealing with a biological system,
and just as methicillin-resistant Staphylo-
coccus aureus (MRSA) casts its shadow
over hospitals in the developed world,
which now hope for ever more diverged
antibiotics, challenging the malaria para-
site with vaccines and drugs will probably
result in the emergence of mutants that
are unaffected by current treatments (see
David et al. [1985] for an early report of
a worrying precedent). Therefore, our pipe-
lines must also continue to deliver thera-
pies that, when intelligently managed, will
continue to be effective. Furthermore,
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must also be engaged in the process and
provided with the infrastructure and train-
ing to contribute to both the development
of therapies and their implementation.
When this is all in place, perhaps then we
can offer genuine hope and, to many more
two-year-olds, wherever they are, an equal
opportunity to a full and productive life.
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